Background
Baroreceptor activation therapy (BAT) is a novel therapeutic option employed in treatment of resistant hypertension (HT) and/or heart failure (HF). Barostim neo is a minimally invasive device baroreceptor activation device that reduces high blood pressure and improves cardiovascular function. Here, we report one case with treatment HT and one with HF, which we treated with Barostim neo. These are the first reported two cases from Turkey.
Methods-Results
First patient was 52-year-old male followed-up for resistant hypertension for 10 years. He had coronary artery disease and on beta-blocker, calcium channel blocker and angiotensin receptor antagonist/diuretic combination. Second patient was a 55 years-old male with ischemic dilated cardiomyopathy. He had NYHA class III-IV functional capacity and not appropriate for cardiac resynchronization therapy. He had a left ventricular ejection fraction of 20% with a LVEDD of 67 mm and LVESD of 59 mm. Barostim neo System implantation procedures were performed without any complication. In patient with HT an average 32/14mmHg decline was recorded on 24-hour blood pressure monitorization after one month. In patient with HF there was increase in functional capacity and six minutes walking distance.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
